CUPRIC CHLORIDE - Generic Drug Details

What are the generic sources for cupric chloride and what is the scope of freedom to operate?

Cupric chloride is the generic ingredient in two branded drugs marketed by Amneal, Exela Pharma, Somerset, Stira, and Hospira, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.

Seven suppliers are listed for this compound.

Summary for CUPRIC CHLORIDE

US Patents:	0
Tradenames:	2
Applicants:	5
NDAs:	5
Finished Product Suppliers / Packagers:	7
Raw Ingredient (Bulk) Api Vendors:	43
Patent Applications:	5,225
What excipients (inactive ingredients) are in CUPRIC CHLORIDE?	CUPRIC CHLORIDE excipients list
DailyMed Link:	CUPRIC CHLORIDE at DailyMed

US Patents and Regulatory Information for CUPRIC CHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Exela Pharma	CUPRIC CHLORIDE	cupric chloride	INJECTABLE;INJECTION	212071-001	Oct 31, 2022	AP	RX	No	No
Stira	CUPRIC CHLORIDE	cupric chloride	INJECTABLE;INJECTION	217626-001	Apr 30, 2024	AP	RX	No	No
Amneal	CUPRIC CHLORIDE	cupric chloride	INJECTABLE;INJECTION	217287-001	Jan 26, 2026		DISCN	No	No
Hospira	CUPRIC CHLORIDE IN PLASTIC CONTAINER	cupric chloride	INJECTABLE;INJECTION	018960-001	Jun 26, 1986	AP	RX	Yes	Yes
Somerset	CUPRIC CHLORIDE	cupric chloride	INJECTABLE;INJECTION	216113-001	Apr 30, 2024	AP	RX	No	No

Cupric Chloride Drug Market Dynamics, Patent Status, FDA Regulation and Financial Outlook

Last updated: August 8, 2026

Cupric chloride is a low-value, hospital-administered trace-element drug used mainly as a copper source in parenteral nutrition. Its commercial profile differs from conventional branded pharmaceuticals: demand is tied to intensive-care utilization, neonatal and pediatric nutrition, home infusion, hospital purchasing contracts, and supply continuity. The product has limited differentiation, no meaningful consumer market, and no publicly disclosed standalone revenue stream.

The financial outlook is stable but modest. Price increases can occur during shortages because hospitals require copper for patients receiving long-term parenteral nutrition, but the market remains exposed to generic competition, contract rebidding, manufacturing concentration, and substitution by multi-trace-element products.

What is cupric chloride used for in pharmaceutical treatment?

Cupric chloride injection is an intravenous source of copper for patients who require parenteral nutrition. Copper is an essential trace element involved in iron metabolism, connective-tissue formation, cellular respiration, pigment formation, and neurological function. The injection is generally diluted into a parenteral-nutrition solution rather than administered as a stand-alone therapeutic course.[1]

Primary clinical uses

Use	Commercial relevance
Adult parenteral nutrition	Core demand source
Neonatal and pediatric parenteral nutrition	High clinical sensitivity and specialized demand
Long-term home parenteral nutrition	Recurring utilization through infusion providers
Copper supplementation when oral intake is inadequate	Secondary demand
Treatment or prevention of copper deficiency	Limited, institution-specific demand

The product is not a mass-market medicine. Most doses are purchased by hospitals, compounding pharmacies, home-infusion providers, and group purchasing organizations.

What is the FDA regulatory status of cupric chloride injection?

Cupric chloride injection is an FDA-regulated prescription drug used as a parenteral nutrition component. U.S. product labeling identifies it as a sterile injectable copper preparation, typically supplied in a single-dose vial and administered only after dilution.[1]

The key regulatory requirements are:

• Sterility and particulate control.
• Accurate copper concentration.
• Compatibility with parenteral-nutrition formulations.
• Control of elemental impurities and extractables.
• Container-closure integrity.
• Stability after dilution and admixture.
• Clear labeling for intravenous use and trace-element dosing.

Because the product is injected directly into the bloodstream, manufacturing controls are more important than the chemical simplicity of cupric chloride. The active ingredient is inexpensive, but sterile injectable production requires qualified facilities, validated processes, environmental controls, and regulatory compliance.

FDA regulatory pathway

Cupric chloride is generally positioned as an established injectable drug rather than a new chemical entity. Commercial products may be approved through an abbreviated or legacy regulatory pathway depending on the product, sponsor, and historical approval record. The FDA Orange Book remains the primary source for determining whether a specific product has listed patents, exclusivity, therapeutic-equivalence information, and approval pathway.[2]

Public labeling does not indicate that cupric chloride has the type of new-drug exclusivity associated with a recently approved branded medicine.

What patents protect cupric chloride injection?

The active ingredient is an old inorganic compound with no apparent commercially meaningful composition-of-matter patent estate. Cupric chloride itself is unlikely to support a new chemical entity patent because the compound has long been known and used in industrial, laboratory, nutritional, and medical applications.

The more relevant IP categories are:

IP category	Likely commercial importance
Cupric chloride composition patent	Very low
Parenteral-nutrition formulation patent	Low to moderate
Container or vial technology	Low to moderate
Sterile manufacturing process	Moderate as know-how, limited as blocking IP
Multi-trace-element formulation	Moderate
Method-of-use patent	Low
Delivery-device patent	Minimal for standard vials

What formulation patents could affect the market?

Potentially relevant protection could cover:

• Copper concentration and dosing ranges.
• Compatibility with amino acids, dextrose, electrolytes, and lipid emulsions.
• Trace-element combinations.
• Stability during storage or after admixture.
• Low-volume pediatric formulations.
• Container systems and oxygen-control methods.

These rights would usually be narrower than a composition patent. They may protect a particular formulation or process without preventing competitors from selling a different cupric chloride injection.

No broad, high-value patent barrier is apparent from the established nature of the product. A company seeking to enter the market would face regulatory and manufacturing requirements more than a fundamental patent obstacle.

When does cupric chloride lose exclusivity?

Cupric chloride has effectively operated in a mature, generic-like market for many years. There is no identifiable product-specific loss-of-exclusivity event comparable to a branded small-molecule medicine approaching patent expiry.

Exclusivity type	Assessment
New chemical entity exclusivity	Not commercially relevant
Five-year new-drug exclusivity	Not expected to be relevant to the established ingredient
Three-year clinical-investigation exclusivity	No apparent market significance
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No material public indication
Patent-based exclusivity	No broad blocking estate identified
Biosimilar exclusivity	Not applicable

The competitive risk is therefore present throughout the product’s commercial life. Manufacturers compete through supply reliability, pricing, hospital contracts, product quality, and regulatory execution.

Does cupric chloride have Orange Book-listed patents?

The Orange Book should be checked at the specific product level because listings can vary by application and sponsor. For a mature injectable trace element, the commercial expectation is that patent-listed exclusivity is limited or absent. The primary Orange Book questions are:

1. Whether the exact cupric chloride product has an Orange Book entry.
2. Whether it is listed as therapeutically equivalent to another product.
3. Whether any patent certifications or use codes exist.
4. Whether the application is approved under an NDA or ANDA.
5. Whether the product has current marketing status.

The presence of an Orange Book entry would not by itself indicate strong patent protection. The relevant issue is whether listed patents cover the product and can delay approval or launch by a competing applicant.[2]

Are Paragraph IV challenges relevant to cupric chloride?

Paragraph IV litigation risk appears low. Paragraph IV challenges are most economically significant when a branded product has active Orange Book patents and substantial sales at risk. Cupric chloride lacks the typical characteristics that generate repeated Paragraph IV disputes:

• No high-value branded franchise.
• No major compound patent.
• Low unit economics.
• Limited sales concentration in a single product.
• Several potential formulation and supplier alternatives.
• Hospital purchasing rather than retail pharmacy demand.

A future applicant could still file a Paragraph IV certification if an approved reference product carried listed patents. The commercial incentive would depend on the reference product’s market share and the ability to obtain manufacturing approval at competitive cost. The likely litigation value would be limited compared with major injectable drugs.

Which companies compete with cupric chloride?

Competition comes from three groups.

Stand-alone cupric chloride suppliers

These suppliers sell copper injection as a separate trace-element product. The commercial advantage is dosing flexibility, especially where a pharmacy wants to customize parenteral nutrition.

Multi-trace-element products

Multi-trace-element injections contain copper with other essential elements such as zinc, manganese, and selenium. They can reduce pharmacy compounding steps and simplify procurement. Their presence creates substitution pressure against stand-alone cupric chloride.

Tralement, for example, is a multi-trace-element product authorized for use as a component of parenteral nutrition in certain adult and pediatric populations, subject to labeling and dosing requirements.[3] The product does not eliminate demand for stand-alone copper because clinical needs vary and some patients require individualized trace-element dosing.

Hospital and compounder alternatives

Hospitals may use:

• Alternative FDA-approved trace-element products.
• Outsourced compounded parenteral-nutrition preparations.
• Hospital pharmacy admixture.
• Products purchased through group purchasing organizations.
• Imported or institution-specific supply channels where legally permitted.

This creates a market in which the relevant competitor is often a procurement solution rather than an identical drug.

What generic entry risks exist for cupric chloride?

Generic entry risk is high in structural terms because the product has limited technical differentiation and no apparent fundamental patent barrier. The principal barriers are operational.

Entry factor	Risk level	Effect
Active-ingredient cost	Low	Cupric chloride is inexpensive
Sterile injectable manufacturing	High	Requires specialized facility and controls
FDA approval	Moderate to high	Product-specific data and compliance required
Hospital qualification	Moderate	Buyers require reliable supply and quality
Contract access	Moderate to high	GPO and distributor relationships matter
Patent blockage	Low	No broad blocking estate apparent
Shortage exposure	High	One supplier disruption can affect availability
Pricing power	Low to moderate	Buyers can switch if alternatives exist

A new entrant would not necessarily need to win large retail share. A small number of hospital and distributor contracts could support a viable business if the entrant maintains supply during disruptions.

What manufacturing and IP barriers affect cupric chloride?

Manufacturing is the principal defensibility source. Cupric chloride is a simple active ingredient, but the finished product must meet injectable-drug standards. Relevant barriers include:

• Qualified sterile filling capacity.
• Validated sterilization and aseptic-processing systems.
• Accurate low-dose filling.
• Raw-material qualification.
• Control of particulate matter and elemental impurities.
• Stability data for the marketed container.
• Admixture compatibility data.
• FDA inspection history.
• Reliable vial, stopper, and packaging supply.
• Distribution through hospital and infusion channels.

Manufacturing know-how can protect margins without creating a conventional patent monopoly. A supplier with a strong compliance record may retain contracts even when competitors offer lower nominal prices.

How does cupric chloride compare with multi-trace-element products?

Factor	Stand-alone cupric chloride	Multi-trace-element injection
Dosing flexibility	High	Lower
Pharmacy convenience	Lower	Higher
Product complexity	Low	Higher
Substitution risk	Exposed to multi-trace products	Exposed to individualized dosing
Patent potential	Low	Higher, depending on formulation
Clinical use	Customized copper supplementation	Broad trace-element replacement
Commercial pricing	Generally low	Potentially higher
Shortage impact	Can be acute if no copper alternative is available	Can affect several trace elements simultaneously

Stand-alone cupric chloride remains useful where clinicians must adjust copper separately. Multi-trace products are more attractive when standardization and pharmacy efficiency are priorities.

What is the financial trajectory for cupric chloride?

No reliable public filings isolate cupric chloride revenue by product, making standalone market size, gross margin, and growth rate difficult to quantify. Manufacturers generally report broader hospital pharmaceuticals, injectables, nutrition products, or geographic segments rather than revenue for one trace-element injection.

Revenue drivers

1. Parenteral-nutrition volume: More patients requiring prolonged intravenous nutrition increase demand.
2. Hospital occupancy and acuity: Intensive-care and neonatal utilization influence volume.
3. Home infusion: Long-term nutrition supports recurring demand.
4. Shortages: Supply disruptions can increase prices and shift share.
5. Contract wins: GPO and distributor agreements can materially affect a small product line.
6. Multi-trace-element adoption: This can reduce demand for stand-alone copper.
7. Manufacturing consolidation: Fewer qualified suppliers can improve pricing but increase volatility.

Margin profile

The active ingredient is low cost, but sterile injectable overhead can be significant. Profitability depends on:

• Fill-finish utilization.
• Batch scale.
• Packaging costs.
• Quality-control expenses.
• Regulatory remediation.
• Freight and cold-chain requirements, where applicable.
• Contract pricing.
• Product shortages and back-order periods.

A mature product normally has limited pricing power under stable supply conditions. Margins may expand temporarily during shortages but can contract quickly when a competitor restores availability.

What litigation and settlement agreements affect cupric chloride?

No major public patent-litigation or settlement landscape is apparent for cupric chloride comparable to high-revenue branded drugs. The low-value nature of the product reduces incentives for extensive patent litigation.

The more material legal risks are likely to involve:

• Manufacturing-quality enforcement.
• Product recalls.
• Supply contracts.
• Distribution agreements.
• Hospital purchasing disputes.
• False or misleading labeling.
• Compounding and outsourcing compliance.
• Antitrust scrutiny if supply becomes concentrated.

Settlement agreements involving Paragraph IV litigation would be commercially significant only if a specific reference product had valuable listed patents. No broad industry settlement framework is evident for cupric chloride.

What generic launch scenarios are most likely?

Base case: stable mature market

Existing suppliers retain hospital contracts, while demand grows slowly with parenteral-nutrition utilization. Prices remain constrained and revenue grows broadly in line with volume and inflation.

Upside case: supply disruption

A manufacturing interruption, recall, or regulatory action removes one or more suppliers. Remaining manufacturers gain volume and may achieve temporary price increases. Hospitals increase safety stock and seek qualified alternatives.

Downside case: substitution by multi-trace products

Hospitals shift from stand-alone copper to multi-trace-element formulations to simplify compounding. Cupric chloride remains clinically necessary for customized dosing but loses routine volume.

Entrant case: low-cost sterile supplier

A new approved supplier enters through hospital and distributor contracts. Price competition increases, but the entrant’s success depends on inspection readiness and consistent availability rather than patent clearance.

How strong is the cupric chloride patent estate?

The patent estate is weak as a blocking asset and moderate only as a formulation or manufacturing-support asset.

Patent-strength dimension	Assessment
Compound protection	Weak or absent
Method-of-use protection	Weak
Formulation protection	Potentially narrow
Manufacturing know-how	Meaningful
Regulatory exclusivity	Limited
Litigation deterrence	Low
Geographic exclusivity	Limited in mature markets

Geographic differences matter. U.S. competition is shaped by FDA approval, Orange Book records, sterile manufacturing capacity, and hospital procurement. European and other markets depend on national authorization systems, tendering, local manufacturing, and reimbursement rules. A company may have commercial protection in one country through supply contracts without holding a strong patent position.

Key Takeaways

• Cupric chloride is a mature injectable trace-element product used primarily in parenteral nutrition.
• Its active ingredient has little apparent composition-of-matter patent value.
• Commercial barriers are sterile manufacturing, FDA compliance, supply reliability, and hospital contracting.
• Paragraph IV litigation and biosimilar risk are low or not applicable.
• Multi-trace-element products are the main functional substitute.
• Public company filings generally do not disclose cupric chloride revenue separately.
• The financial trajectory is likely low-growth and volume-driven, with temporary upside during shortages.
• The most important investment variable is supply continuity, not patent expiry.
• A new entrant could compete without overcoming a significant patent estate, but it would need validated sterile capacity and hospital-channel access.

FAQs About Cupric Chloride Pharmaceutical Market

Is cupric chloride a generic drug?

Cupric chloride is commercially treated as a mature prescription injectable with generic-like economics, although the exact FDA approval pathway and therapeutic-equivalence status depend on the individual marketed product.

Is cupric chloride subject to biosimilar competition?

No. Cupric chloride is an inorganic small-molecule compound, not a biologic. Biosimilar regulation does not apply.

Can hospitals replace cupric chloride with Tralement?

In some cases, yes, but substitution depends on the patient’s copper requirement, the complete trace-element regimen, product labeling, and the parenteral-nutrition formulation. Stand-alone copper remains useful when trace elements must be adjusted separately.[1][3]

Does cupric chloride have a high shortage risk?

Its shortage risk can be meaningful because the product is sterile, low volume, and supplied by a limited number of qualified manufacturers. A single facility interruption can affect hospital availability even when underlying clinical demand is stable.

Is cupric chloride an attractive pharmaceutical licensing asset?

As a standalone molecule, it has limited licensing value. The more credible licensing opportunities involve sterile injectable capacity, hospital distribution, multi-trace-element formulations, or manufacturing technology rather than exclusive rights to cupric chloride itself.

References

1. U.S. Food and Drug Administration. (n.d.). Cupric chloride injection prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (n.d.). Tralement prescribing information. DailyMed.
4. American Society for Parenteral and Enteral Nutrition. (2020). Appropriate dosing for parenteral nutrition: Trace elements and clinical practice guidance. ASPEN.